ArticleCancer2025
Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBlack patients with pancreatic ductal adenocarcinoma (PDAC) are less likely to have a major pathologic response (MPR) after neoadjuvant chemotherapy (NAC). Data suggest lower baseline carbohydrate antigen 19-9 (CA 19-9) among Black patients. Whether CA 19-9 nonproduction contributes to racial differences in NAC response was evaluated, and the biological mechanisms underlying the reduced response in CA 19-9 nonproducers (CAnonprod) were investigated.
methodsBlack and White patients with PDAC who received ≥2 NAC cycles and pancreatectomy at seven centers were reviewed. Patients were categorized as CA 19-9 producers (CAprod; CA 19-9 > 5 U/mL) or CAnonprod (CA 19-9 ≤ 5 U/mL). Univariable and multivariable models assessed CAnonprod rates by race and the association of CAnonprod with MPR. The Pancreatic Cancer Action Network's SPARK platform was queried for genomic data. Differentially mutated genes were identified by Fisher exact test; differentially expressed gene analysis used an absolute fold change of ≥2 and an adjusted p value of <.05.
resultsAmong 415 patients (385 CAprod and 30 CAnonprod), Black patients comprised more CAnonprod than CAprod (50% vs. 13%; p < .01). MPR rates were lower among CAnonprod versus CAprod (8% vs. 26%; p = .03). CA nonproduction was associated with decreased odds of an MPR (odds ratio [OR], 0.21; 95% CI, 0.04-0.99), and Black race was associated with increased odds of CA 19-9 nonproduction (OR, 8.7; 95% CI, 3.8-19.7). CAnonprod had higher rates of SWI/SNF alterations than CAprod (52% vs. 34%; p < .01; p-adjusted, not significant). LIPF was downregulated and CTCFL was upregulated in CAnonprod.
conclusionsCA 19-9 nonproduction is more prevalent in Black patients, and potentially mediates lower rates of MPR. CAnonprod have a distinct molecular profile, which suggests a biological basis for racial differences in chemoresponsivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.